Cogent Biosciences, Inc.
COGT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622229
In the last 90 days, Cogent Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 325 institutions reported holding it in 13F filings for Q2 2026, worth $7.50B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $5.51B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.69M in total
- 1
- 13F holdersQ2 2026, +21 vs. previous quarter
- 325
- 13F valueReported value at the end of Q2 2026
- $7.50B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$328.9M
- No comparable prior period
- Free cash flow, FY2025
- -$266.0M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 19.7M
- Shares sold short
- Change
- +198.8K
- +1.0% vs. previous
- Days to cover
- 8.94
- At average daily volume
Superinvestors holding COGT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding COGT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Cogent Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 (view filing)5:01 PM ET | Aug 27 | 4 days | Morris ArleneDirector | SSale | −45.5K | $37.12 | −$1.69M | −100.0%0 after | 2 lots10b5-1 |
| Mar 31, 2026 (view filing) | Mar 31 | Same day | Fairmount Funds Management LLCDirector | SSale | −7.00M | $34.66 | −$242.6M | −56.0%5.50M after | |
| Jan 22, 2026 (view filing) | Jan 22 | Same day | Fairmount Funds Management LLCDirector | SSale | −3.50M | $36.40 | −$127.4M | −38.9%5.50M after | |
| Dec 30, 2025 (view filing) | Dec 26 | 4 days | Kearns EvanChief Legal Officer | SSale | −65.0K | $38.70 | −$2.52M | −37.3%109.4K after | |
| Dec 30, 2025 (view filing) | Dec 26 | 4 days | Green John L.Chief Financial Officer | SSale | −77.0K | $38.68 | −$2.98M | −36.9%131.8K after | |
| Dec 30, 2025 (view filing) | Dec 26 | 4 days | Sachs JessicaChief Medical Officer | SSale | −82.6K | $38.70 | −$3.20M | −38.2%133.9K after | |
| Dec 30, 2025 (view filing) | Dec 26 | 4 days | Robinson John EdwardChief Scientific Officer | SSale | −90.0K | $38.74 | −$3.49M | −39.1%140.0K after | |
| Jul 14, 2025 (view filing) | Jul 10 | 4 days | Fairmount Funds Management LLCDirector | PPurchase | +2.78M | $9.00 | +$25.0M | +44.6%9.00M after | |
| Jan 15, 2025 (view filing) | Jan 14 | 1 day | Pinnow ColeChief Commercial Officer | PPurchase | +43.8K | $7.60 | +$332.5K | +2,085.3%45.8K after | |
| Jun 13, 2023 (view filing) | Jun 9 | 4 days | Fairmount Funds Management LLC10% Owner, Other: See Remarks | PPurchase | +800.0K | $12.00 | +$9.60M | +32.4%3.27M after |
Top 10 13F holders, Q2 2026
See all 325 holdersThe largest institutional positions in Cogent Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 25,681,174 | $993.9M | 0.04% | +2,558,426+11.1% | Added |
| BlackRock, Inc. | 17,352,646 | $671.5M | 0.01% | +1,307,632+8.1% | Added |
| Vanguard Portfolio Management LLC | 8,072,411 | $312.4M | 0.01% | +739,078+10.1% | Added |
| Vanguard Capital Management LLC | 7,412,330 | $286.9M | 0.01% | +517,371+7.5% | Added |
| State Street Corp | 6,964,919 | $269.5M | 0.01% | +1,301,376+23.0% | Added |
| Jupiter Topco LLC | 6,624,848 | $256.4M | 0.10% | +6,624,848 | New |
| Fairmount Funds Management LLC | 5,503,418 | $213.0M | 14.08% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 5,006,104 | $193.7M | 2.02% | −4,037,799−44.6% | Reduced |
| TCG Crossover Management, LLC | 4,854,436 | $187.9M | 4.52% | −92,458−1.9% | Reduced |
| Price T Rowe Associates Inc | 4,652,727 | $180.1M | 0.02% | +1,439,912+44.8% | Added |
Holders of 5% or more of COGT
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Cogent Biosciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%16.6M shares | – | Feb 9, 20244 filings | Feb 12, 2025 | SEC |
| Fairmount Funds Management LLC | 13D/A | 8.60%15.4M shares | −1.30 ppfrom 9.90% | Jun 21, 202210 filings | Mar 31, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 8.00%13.6M shares | +1.50 ppfrom 6.50% | Jan 21, 20263 filings | Jul 27, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.08%8.69M shares | New | Jul 31, 20261 filing | Jul 31, 2026 | SEC |
Politician trades
All politician trades in COGT1 member of Congress reported 1 trade in Cogent Biosciences, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jan 20, 2023 |  Chris Jacobs House · NY | Buy | $1K-$15K |
House · NY · Jan 20, 2023
Buy$1K-$15K